Skip to main content

Virpax Pharmaceuticals, Inc. (VRPX)

NASDAQ: VRPX · IEX Real-Time Price · USD
4.79
+0.09 (1.92%)
After-hours:Sep 24, 2021 7:58 PM EDT
4.70
-0.26 (-5.24%)
At close: Sep 24, 4:00 PM
Market Cap55.06M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out11.72M
EPS (ttm)-1.88
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,165,533
Open4.89
Previous Close4.96
Day's Range4.67 - 4.97
52-Week Range3.70 - 36.00
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 11, 2021

About VRPX

Virpax Pharmaceuticals, Inc., a preclinical stage biopharmaceutical company, develops and manufactures non-opioid and non-addictive pharmaceutical products using drug delivery systems for pain management. The company offers products, such as Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; Probudur (LBL100), long-acting bupivacaine liposomal gel for postoperative pain management; OSF200 for chronic osteoarthritis of the knee; and NES100 (Envelta), an exogenous enkephalin intranasal spray for acute and chronic pain...

IndustryBiotechnology
IPO DateFeb 17, 2021
Employees2
Stock ExchangeNASDAQ
Ticker SymbolVRPX
Full Company Profile

Financial Performance

Financial Statements

News

Best Penny Stocks To Buy Today? Retail Traders Are Watching These Now

Penny stocks bouncing back after the stock market sell-off The post Best Penny Stocks To Buy Today? Retail Traders Are Watching These Now appeared first on Penny Stocks to Buy, Picks, News and Informati...

Other symbols:BESTCYDY
5 days ago - PennyStocks

Virpax to Develop Intranasal Cannabidiol Product for the Management of Epilepsy in Adults and Children

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS disorder...

5 days ago - Business Wire

Virpax® Pharmaceuticals Announces Closing of $40 Million Public Offering of Common Stock

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today an...

1 week ago - Business Wire

Virpax® Pharmaceuticals Announces Pricing of $40 Million Public Offering of Common Stock

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today an...

1 week ago - Business Wire

Virpax Pharmaceuticals Announces Poster Presentation for Envelta™ at PAINWeek 2021

BERWYN, Pa.--(BUSINESS WIRE)-- #PAINWeek--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced it will present a poster on Leucine Enkephalin as a potential analgesic...

3 weeks ago - Business Wire

Virpax Announces MMS019 Manufacturing and Supply Agreement

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS and anti...

4 weeks ago - Business Wire

Short Squeeze Stocks: VRPX, CRDL and 3 Others Experts Think Are Ready to Pop

As we begin another week, here's a look at some of the best short squeeze stocks available to investors according to research from Fintel. The post Short Squeeze Stocks: VRPX, CRDL and 3 Others Experts ...

Other symbols:NAOV
1 month ago - InvestorPlace

Should you invest in Virpax Pharma as stock soars more than 40%?

On Wednesday, Virpax Pharmaceuticals Inc. (NASDAQ:VRPX) shares soared more than 97% before pulling back later for a net intraday gain of 43%. The stock is now up more than 470% from its Monday close fol...

1 month ago - Invezz

VRPX Stock: What Investors Are Saying About Virpax Pharma as Shares Continue to Fly

Shares of VRPX stock continue to blow up on Wednesday after Virpax Pharmaceuticals' massive business announcement on Tuesday. The post VRPX Stock: What Investors Are Saying About Virpax Pharma as Shares...

1 month ago - InvestorPlace

Why Virpax Pharmaceuticals Shares Are Soaring Today

Virpax Pharmaceuticals Inc (NASDAQ: VRPX) is surging higher Tuesday after the company announced that it received a written pre-investigational new drug response from the U.S. Food and Drug Administratio...

1 month ago - Benzinga

Here's why Virpax Pharmaceuticals is up 280% on Tuesday

Virpax Pharmaceuticals Inc. (NASDAQ: VRPX) said on Tuesday it received a written pre-IND (investigational new drug) response from the U.S. FDA (Food and Drug Administration) for MMS019 that supports fur...

1 month ago - Invezz

VRPX Stock: 6 Things for Virpax Pharma Investors to Know as Shares Rocket Over 250%

Virpax Pharma (VRPX) stock is rocketing higher on Tuesday after getting a response from the FDA concerning an anti-viral barrier product. The post VRPX Stock: 6 Things for Virpax Pharma Investors to Kno...

1 month ago - InvestorPlace

Why Virpax Pharmaceuticals Stock Flying Higher?

Virpax Pharmaceuticals Inc (NASDAQ: VRPX) has received a written pre-investigational new drug (pre-IND) response from the FDA regarding MMS019. The drug candidate is a high-density molecular masking spr...

1 month ago - Benzinga

Virpax® Pharmaceuticals Receives FDA Response and Guidance on MMS019

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS and anti...

1 month ago - Business Wire

Virpax Pharmaceuticals Reports 2021 Second Quarter Results and Recent Developments

BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended June 30, 2021, and other re...

1 month ago - Business Wire

Virpax® Pharmaceuticals Strengthens Board of Directors with the Appointment of Gerald W. Bruce and Michael F.

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing pharmaceutical product candidates for pain managemen...

1 month ago - Business Wire

Virpax Pharmaceuticals Provides Progress Update on Product Candidates

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today is providing a progress update on its pipeline of product candidates following the C...

2 months ago - Business Wire

Virpax to Use Envelta™ IND Enabling Study Results for Two Additional Indications

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), today announced that the Investigational New Drug (IND) Application enabling studies for...

3 months ago - Business Wire

Virpax Pharmaceuticals to Present at LD Micro Invitational XI Event on Wednesday, June 9th at 4:30 PM ET

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing non-addictive, non-opioid pharmaceutical products fo...

3 months ago - Business Wire

Virpax Pharmaceuticals Reports 2021 First Quarter Results and Recent Developments

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2021, and other rec...

4 months ago - Business Wire

Virpax Pharmaceuticals Engages Torreya Capital to Advise on Global Partnering Efforts

BERWYN, Pa.--(BUSINESS WIRE)-- #licensing--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced that the Company has engaged Torreya Capital, LLC (Torreya) to serve a...

5 months ago - Business Wire

Virpax's Anti-Viral Candidate Reduced Nasal, Brain Viral Load In Animal Study

Virpax Pharmaceuticals Inc (NASDAQ: VRPX) has announced preclinical results of MMS019, its anti-viral product candidate for respiratory viruses. MMS019 is a high-density molecular masking spray the Comp...

5 months ago - Benzinga

Virpax's MMS019 Reduced Nasal and Brain Viral Load in Animal Study

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical product candidates for pain managemen...

5 months ago - Business Wire

Virpax's Liposomal Bupivacaine Candidate Associated With No Neurotoxicity In Animal Studies

Virpax Pharmaceuticals Inc (NASDAQ: VRPX) has announced data from a sciatic nerve preclinical study designed to evaluate Probudur, Virpax's liposomal bupivacaine product candidate. This study's objectiv...

5 months ago - Benzinga

Virpax Announces Results of Probudur(TM) in Animal Study

BERWYN, PA / ACCESSWIRE / April 5, 2021 / Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical product candidates for pain managem...

5 months ago - Accesswire